Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

NCT03150160 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma

Interventions

DRUG: brinzolamide 1%/brimonidine 0.2% fixed combination
DRUG: Placebo
DRUG: travoprost 0.004% ophthalmic solution

Sponsor

Novartis Pharmaceuticals